Teva pharmaceuticals, Catalyst

Catalyst settles with Teva, staving off Firdapse generic until 2035
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med Firdapse, Catalyst Pharmaceutical has repeatedly emerged triumphant over its d | Thanks to a new settlement with Catalyst,
Catalyst settlement with Teva a positive event, says BofA
BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement
Teva Pharmaceutical Industries Ltd (TEVA) Stock: Understanding Its Underlying Value
Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.24 which represents a decrease of $-0.06 or -0.28% from the prior close of $21.3. The stock opened at $21.4 and touched a low of $21.
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock was recently at $22.
Catalyst Pharmaceuticals up 18% after resumption following Teva settlement
Shares of Catalyst Pharmaceuticals (CPRX) have resumed trading and are higher after the company announced that the company and its licensor
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA regarding the Firdapse (amifampridine) patent litigation.
Catalyst stock climbs 15% on Firdapse litigation settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva (TEVA) that would delay the launch of a generic version of its drug Firdapse until at least 2035.
bovnews1d
Teva Pharmaceutical Industries Ltd (TEVA) Stock: Surpassing Expectations in the Market?
Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...
Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday
We recently compiled a list of the 10 Firms Kick Off 2025 Trading in The Red. In this article, we are going to take a look at ...
ETF Daily News13d
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Roberto Mignone Sells 286,000 Shares
NYSE:TEVA opened at $22.62 on Friday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.39 and a ...
globes.co.il1d
US analysts list Teva, Wix in 2025 top picks
Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...
24/7 Wall St1d
Teva- Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well ...
Duvakitug And Teva's Growth: A Game Changer In Pharma
Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here ...
Pharmaceutical Technology3d
TEV-56278 by Teva Pharmaceutical Industries for Solid Tumor: Likelihood of Approval
TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.
CSR Wire2d
Why Diversity in Clinical Trials Is So Important
Clinical trials are essential for the development of health care products, and it is increasingly recognized that there is a ...
Spinal Cord Injury Therapeutics Market Investment Opportunities: A Guide To 2031 Teva Pharmaceutical Industries Ltd.
Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.